Exclusive-US weighs allowing most pharma licensing deals with China, sources say

The U.S. Treasury is drafting outbound-investment rules that would likely allow most U.S. pharmaceutical companies to continue licensing and investing in Chinese drug developers, excluding pathogen-related or potentially weaponizable biotechnology. The proposed approach could preserve billions of dollars in deal activity: foreign licensing deals involving Chinese biotech totaled $115 billion last year, while Bristol Myers Squibb and Pfizer recently announced China-linked collaborations worth up to $15.2 billion and $10.5 billion, respectively. Rules remain unfinished and could change following political input, with some lawmakers and smaller biotech companies seeking substantially tighter restrictions on China-related pharmaceutical transactions.

Analysis

A permissive framework would preserve a capital-efficient external-R&D channel precisely as large pharma faces rising internal discovery costs and patent-expiry pressure. PFE and BMY should benefit less from headline revenue than from lower pipeline replacement cost: access to earlier-stage assets can reduce the need for premium-priced U.S. biotech acquisitions, supporting long-run ROIC and limiting the dilution/debt typically associated with large M&A. The near-term equity impact is modest because licensing economics are milestone-heavy, but confirmed rules would improve the probability-weighted value of oncology and immunology pipeline replenishment over 6-18 months.

The more important relative-value implication is negative for U.S. small/mid-cap biotech platforms whose valuations embed strategic-buyout scarcity. If multinational pharma can source comparable assets from China at lower upfront payments, XBI constituents without differentiated clinical data, validated targets, or commercial infrastructure could see lower partnering multiples. DNA is particularly exposed: its synthetic-biology adjacency creates greater risk that a final rule's pathogen, dual-use, or enabling-biotechnology definitions are broader than currently anticipated, while its business model is already sensitive to customer funding and regulatory perception.

Consensus may overstate the durability of the apparent carve-out. Treasury's eventual definitions, reporting requirements, and enforcement burden matter more than a nominal exemption; even permitted transactions may face longer diligence cycles and higher compliance costs. The Trump-Xi meeting is a binary near-term policy-risk event, while bipartisan pressure to broaden biotech restrictions remains a 6-12 month overhang; a restrictive definition of platform biotechnology would reverse the relative trade quickly.

Key Decisions for Investors

• Maintain or initiate a 3-6 month long PFE / short XBI pair after Treasury publishes text confirming ordinary therapeutic licensing is excluded. PFE has pipeline-optionality upside with lower dependence on a single asset outcome; short XBI hedges sector beta and captures potential compression in undifferentiated biotech partnering multiples. Exit if the rule explicitly includes therapeutic licensing or if PFE reduces external-business-development guidance.
• Prefer BMY over smaller pre-revenue oncology biotech suppliers for 6-18 months, but size modestly: external sourcing can extend franchise durability at lower capital intensity, yet the earnings impact will lag. Falsification is a material upward revision in projected acquisition spend, weak post-deal clinical readouts, or a policy requirement that makes Chinese-origin program development commercially impractical.
• Avoid adding to DNA ahead of final regulatory definitions; treat any relief rally as an opportunity to reduce exposure unless Treasury clearly distinguishes drug-asset licensing from broad synthetic-biology tools. A broad dual-use carve-out, new reporting thresholds, or management disclosure of delayed customer programs would be downside catalysts.
• Set alerts around the Trump-Xi meeting and the Treasury rule publication rather than trading the current reporting. The actionable data points are the definition of covered biotechnology, treatment of joint ventures versus licenses, grandfathering of existing deals, and any mandatory review timeline; absent those details, the signal is insufficient for a directional sector-wide position.